Organ distribution and biological compatibility of surface-functionalized reduced graphene oxide. (20th November 2019)

• Record Type: Journal Article
• Authors: Cherian, R S; Anju, S; Paul, Willi; Sabareeswaran, A; Mohanan, P V
• Is Part Of: Nanotechnology. Volume 31:Number 7(2020)
• Publication Date: 2019-11-20
• Subjects: Raman mapping -- reduced graphene oxide -- BBB -- feto-placental transmission -- organ distribution; Nanotechnology -- Periodicals; Nanotechnology -- Periodicals; Nanotechnology; Publications périodiques; Nanotechnologies; Periodicals; 620.5
• DOI: 10.1088/1361-6528/ab4bff
• Languages: English
• ISSNs: 0957-4484

Abstract

Abstract: Graphene is an sp 2 hybridized allotrope of carbon with a honeycomb lattice structure that has many applications in biomedicine owing to its unique physico-chemical properties. Graphene has attracted much interest from scientists for its biomedical potential, including in drug/gene delivery, fluorescent labeling of target analytes, tissue engineering, regenerative medicine and MRI contrast enhancement. However, there are very limited data available concerning the toxicity of graphene, and efforts have been made to study the bio-nano interactions of Pluronic functionalized reduced graphene oxide (rGO-P) in animal models. The present study aimed to evaluate the systemic toxicity of rGO-P and its ability to cross the blood–brain barrier in Swiss Albino mice subject to acute exposure to 10 mg kg −1 body weight of rGO-P. Prolonged exposure was evaluated in female Wistar rats by analyzing feto-placental transmission and any associated developmental neurotoxicity after intravenous administration of 5 mg kg −1 and 10 mg kg −1 body weight of rGO-P. Biodistribution analysis using confocal Raman mapping indicated that tiny amounts of rGO-P accumulated in major organs of both dams and pups, with no evident toxic response. The accumulation of rGO-P in various tissues of rat pups born to treated dams is ample evidence of feto-placental transmission. The present study clearly suggests that rGO-P is not toxic under any of the experimental conditions. These findings can therefore be carried forward for application of rGO-P in drug/gene delivery, early diagnosis and treatment of various diseases in neonates and adults. The results of the study show that rGO-P is an auspicious and promising material for future healthcare applications.